香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因依賴該等內容而引致的任何損失承擔任何責任。 InnoCare Pharma Limited 諾誠健華醫藥有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：9969） 承授人及獲授受限制股份 單位的數目： 授予兩名僱員參與者1,400,000份受限制股份單位。 概無承授人須個別披露。 購買價： 每股香港股份0.178美元（約1.39港元） 根據2023年股權激勵計劃 授予受限制股份單位 根據上市規則第17.06A條，董事會宣佈於2025年12月31日，本公司根據2023年 股權激勵計劃授予兩名承授人1,400,000份受限制股份單位，相當於本公司於本 公告日期已發行股份總數的約0.08%。 授予受限制股份單位的詳情 授予承授人受限制股份單位的詳情如下： 授出日期： 2025年12月31日 – 1 – 於授出日期股份的 收市價： (i) 每股香港股份12.3港元；及 (ii) 每股人民幣股份人民幣20.52元（約2 ...

机构持仓方面，截止2025年9月30日，诺诚健华十大流通股东中，富国精准医疗灵活配置混合A （005176）位居第六大流通股东，持股1215.49万股，相比上期减少42.71万股。万家优选（161903）位 居第七大流通股东，持股1000.00万股，为新进股东。平安医疗健康混合A（003032）位居第八大流通股 东，持股862.66万股，为新进股东。工银前沿医疗股票A（001717）位居第九大流通股东，持股800.00 万股，为新进股东。汇添富创新医药混合A（006113）位居第十大流通股东，持股686.03万股，相比上 期减少74.34万股。中欧医疗健康混合A（003095）、鹏华医药科技股票A（001230）、易方达医疗保健 行业混合A（110023）退出十大流通股东之列。 诺诚健华今年以来股价涨74.35%，近5个交易日跌2.68%，近20日跌17.30%，近60日跌23.75%。 责任编辑：小浪快报 12月25日，诺诚健华盘中下跌2.01%，截至10:06，报21.41元/股，成交5115.47万元，换手率0.88%，总 市值377.81亿元。 诺诚健华所属申万行业为：医药生物-化学制药-化学制剂。所 ...

Core Viewpoint - The report from Guoyuan International highlights the strong performance of Oubutini in the SLE IIb trial, indicating significant potential for the company in the autoimmune disease sector [1] Group 1: Clinical Trial Results - Oubutini demonstrated a SRI-4 response rate of 57.1% in the 75mg group, significantly higher than the placebo group at 34.4% [1] - In the subgroup with baseline BILAG≥1A or ≥2B, the SRI-4 response rate improved by 35% compared to the placebo group [1] - In the subgroup with BILAG≥1A or ≥2B and SLEDAI-2K score ≥4, the improvement was 43% [1] Group 2: Regulatory Approvals and Product Pipeline - The CDE has approved the initiation of a Phase III clinical trial for Oubutini in treating SLE, with the first patient expected to be enrolled in Q1 2026 [1] - The company has accelerated its product pipeline with the approval of Zolacutini for market release [1] - The new TYK2 inhibitor ICP-488 for treating cutaneous lupus erythematosus (CLE) has also received CDE approval to commence Phase II clinical trials [1] Group 3: Financial Position and Valuation - The company holds approximately 7.2 billion yuan in cash and related accounts, sufficient for ongoing innovative research [1] - The company is driven by scientific innovation, showcasing strong product capabilities [1] - Based on the DCF model, a target price of 16.81 HKD is set, indicating a potential upside of 28% from the current price [1]

Group 1 - The core viewpoint of the report is that Nuo Cheng Jian Hua (09969) is expected to achieve revenues of RMB 2.01 billion, RMB 2.06 billion, and RMB 2.56 billion for the years 2025-2027, with net profits of RMB 117 million, RMB 17 million, and RMB 188 million respectively. The company holds approximately RMB 7.2 billion in cash and equivalents, which is sufficient for innovative research. The company is driven by scientific innovation and has strong product capabilities. A DCF model gives a target price of HKD 16.81, indicating a potential upside of 28% from the current price [1] Group 2 - The company focuses on hematological malignancies, solid tumors, and autoimmune diseases. The drug Oubutini has shown excellent performance in the SLE IIb trial, with a SRI-4 response rate of 57.1% in the 75mg group, significantly higher than the placebo group at 34.4%. In subgroups with baseline BILAG≥1A or ≥2B, the response rate improved by 35%, and in those with BILAG≥1A or ≥2B and SLEDAI-2K score ≥4, it improved by 43%. The CDE has approved the initiation of a Phase III clinical trial for Oubutini in SLE, with the first patient expected to be enrolled in Q1 2026 [2] Group 3 - The product pipeline is advancing rapidly, with the new TYK2 inhibitor ICP-488 approved for Phase II clinical trials for cutaneous lupus erythematosus (CLE). ICP-488 specifically binds to the TYK2 JH2 domain, blocking the signaling of inflammatory cytokines such as IL-23, IL-12, and type I interferons. The NMPA has approved the company's Zolbetin (ICP-723) for treating adult and adolescent patients with NTRK fusion gene-positive solid tumors, showing excellent clinical data with an objective response rate of 89.1% and a disease control rate of 96.4%. The 24-month PFS is 77.4%, and the 24-month OS is 90.8%, outperforming first-generation TRK inhibitors. The Phase III registration trial for Oubutini in immune thrombocytopenia (ITP) has completed patient enrollment, with plans to submit a new drug application in the first half of 2026 [3] Group 4 - The company has made significant progress in business development, reaching an agreement with Zenas Bio Pharma in October 2025. Zenas has been granted rights for Oubutini for non-oncological indications outside Greater China and Southeast Asia, as well as for multiple sclerosis globally. Zenas will pay a cash upfront of USD 100 million. The total potential value of this transaction exceeds USD 2 billion, and the collaboration with Zenas will significantly accelerate the overseas clinical development of products [4]

Core Viewpoint - Guoyuan International expects Nuo Cheng Jianhua (09969) to achieve revenues of RMB 2.01 billion, 2.06 billion, and 2.56 billion for the years 2025-2027, with net profits of RMB 117 million, 17 million, and 188 million respectively. The company holds approximately RMB 7.2 billion in cash and equivalents, sufficient for innovative research. The company is driven by scientific innovation and has strong product capabilities. A DCF model gives a target price of HKD 16.81, indicating a potential upside of 28% from the current price [1]. Group 1 - Acalabrutinib shows excellent performance in SLE IIb trials, with a SRI-4 response rate of 57.1% in the 75mg group, significantly higher than the placebo group at 34.4%. In subgroups with baseline BILAG≥1A or ≥2B, the response rate improved by 35%, and in those with BILAG≥1A or ≥2B and SLEDAI-2K score ≥4, it improved by 43%. The CDE has approved the initiation of Phase III clinical trials for Acalabrutinib in SLE, with the first patient expected to be enrolled in Q1 2026 [2]. Group 2 - The company has accelerated its product pipeline, with the new TYK2 inhibitor ICP-488 approved for Phase II clinical trials for cutaneous lupus erythematosus (CLE). ICP-488 specifically binds to the TYK2 JH2 domain, blocking the signaling of inflammatory cytokines such as IL-23, IL-12, and type I interferons. The NMPA has approved the company's Entrectinib (ICP-723) for treating adult and adolescent patients with NTRK fusion gene-positive solid tumors, showing high objective response rates (89.1%) and disease control rates (96.4%), with a 24-month PFS of 77.4% and OS of 90.8%, outperforming first-generation TRK inhibitors. Acalabrutinib's Phase III registration trial for immune thrombocytopenia (ITP) in China has completed patient enrollment, with plans to submit a new drug application in H1 2026 [3]. Group 3 - The company has made significant progress in business development, reaching an agreement with ZenasBio Pharma in October 2025. Zenas has been granted rights for Acalabrutinib for non-oncology indications outside Greater China and Southeast Asia, as well as global rights for multiple sclerosis; IL-17i rights are granted for regions outside Greater China and Southeast Asia, and global rights for CNS TYK2i. Zenas will pay a cash upfront of USD 100 million, with the total potential value of the deal exceeding USD 2 billion, which will significantly accelerate the overseas clinical development of products [4].

Core Viewpoint - InnoCare Pharma has received approval for a phase II clinical trial of its TYK2 inhibitor ICP-488 for treating cutaneous lupus erythematosus, marking a significant step in addressing unmet medical needs in autoimmune diseases [1][4]. Company Overview - InnoCare Pharma is a biopharmaceutical company focused on developing first-in-class and best-in-class drugs for cancer and autoimmune diseases, with operations in China and the United States [5]. Product Details - ICP-488 is an oral, potent, and selective TYK2 allosteric inhibitor that blocks the signal transduction of inflammatory cytokines, potentially offering a new treatment option for autoimmune diseases [2]. - The drug has shown favorable efficacy and safety in a phase II clinical trial for psoriasis, with plans for a phase III study nearing completion [4]. Disease Context - Cutaneous lupus erythematosus (CLE) is a common autoimmune disease characterized by skin lesions, which can progress to systemic lupus erythematosus affecting multiple organs [3].

Group 1 - The core point of the news is that Innovent Biologics has received approval from the National Medical Products Administration (NMPA) to conduct Phase II clinical trials for its novel TYK2 inhibitor ICP-488, aimed at treating Cutaneous Lupus Erythematosus (CLE) [1] - ICP-488 is an oral, highly selective TYK2 allosteric inhibitor that blocks the signaling of inflammatory cytokines such as IL-23, IL-12, and type I interferons, thereby inhibiting the pathological processes of autoimmune and inflammatory diseases [1] - CLE is a common type of lupus characterized by diverse skin lesions, with some patients potentially progressing to systemic lupus erythematosus affecting internal organs [1] Group 2 - Innovent Biologics is a commercial-stage biopharmaceutical high-tech company focused on the development of novel drugs for malignant tumors and autoimmune diseases [2] - The company has multiple new drug products at various stages of commercialization, clinical trials, and preclinical development [2] - Innovent Biologics has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States [2]

本文源自：金融界AI电报 港股生物医药概念股回升，荣昌生物(09995.HK)涨超2%，泰格医药(03347.HK)、诺诚健华(09969.HK)、 科伦博泰生物-B(06990.HK)、百济神州(06160.HK)等个股跟涨。 ...

北京商报讯（记者 王寅浩 宋雨盈）12月23日，诺诚健华宣布，公司自主研发的新型TYK2抑制剂ICP- 488治疗皮肤型红斑狼疮获国家药品监督管理局药品审评中心批准开展II期临床试验。 据悉，ICP-488是一款口服的高选择性TYK2变构抑制剂，通过特异性结合TYK2 JH2结构域，阻断IL- 23、IL-12和I型干扰素等炎性细胞因子的信号转导，从而抑制自身免疫性疾病和炎症性疾病的病理过 程。 ...

人民财讯12月23日电，诺诚健华今日宣布，公司自主研发的新型TYK2抑制剂ICP-488治疗皮肤型红斑狼 疮(CLE)获国家药品监督管理局(NMPA)药品审评中心(CDE)批准开展Ⅱ期临床试验。 ...